Standard BioTools Inc. is a biotechnology company that specializes in the development and commercialization of innovative tools and technologies for life sciences research and diagnostics. The company focuses on providing advanced solutions to enable researchers to better understand complex biological systems and streamline workflows in areas such as genomics, proteomics, and cell biology. By leveraging cutting-edge technologies and collaborative relationships with scientific communities, Standard BioTools aims to enhance the efficiency and accuracy of biological analysis, ultimately contributing to breakthroughs in healthcare and therapeutic development. Read More
This week, several emerging stocks are capturing investor attention with headline-making developments across defense tech, mining, HR, crypto gaming, wellness, and AI-driven diagnostics.
The Dow Jones index closed higher by around 75 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Believes that the Proposed Merger Grossly Undervalues SomaLogic and Ignores its Revolutionary Products, Considerable Cash Position, and Strong Balance Sheet
NEW YORK, Dec. 17, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”) (NASDAQ: SLGC).
NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”) (NASDAQ: SLGC).
NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating the proposed all-stock merger between Standard BioTools Inc. (“Standard BioTools”) (NASDAQ: LAB) and SomaLogic, Inc. (“SomaLogic”) (NASDAQ: SLGC).
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SomaLogic, Inc. (NasdaqGM: SLGC) to Standard BioTools Inc. (“the Company”) (NasdaqGS: LAB). Under the terms of the proposed transaction, upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SomaLogic, Inc. (NasdaqGM: SLGC) to Standard BioTools Inc. (“the Company”) (NasdaqGS: LAB). Under the terms of the proposed transaction, upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. KSF is seeking to determine whether the transaction and the process that led to it are adequate and fair to the Company’s shareholders.
